2017
Profiling gene expression of antimony response genes in Leishmania (Viannia) panamensis and infected macrophages and its relationship with drug susceptibility
Barrera MC, Rojas LJ, Weiss A, Fernandez O, McMahon-Pratt D, Saravia NG, Gomez MA. Profiling gene expression of antimony response genes in Leishmania (Viannia) panamensis and infected macrophages and its relationship with drug susceptibility. Acta Tropica 2017, 176: 355-363. PMID: 28843396, PMCID: PMC5633519, DOI: 10.1016/j.actatropica.2017.08.017.Peer-Reviewed Original ResearchConceptsLeishmania resistanceDrug susceptibilityDrug resistanceHost cell gene expressionClinical strainsCell gene expressionExpression of ABCA2THP-1 cellsPrimary human macrophagesLeishmania susceptibilityGene expressionAntimonial drugsCutaneous leishmaniasisInfected macrophagesLeishmania panamensisIntracellular amastigotesHuman macrophagesResistant strainsSusceptible parasitesAntimonialsIntracellular parasitesLeishmania speciesMacrophagesL. panamensisAQP-9
2014
Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia
Fernández OL, Diaz-Toro Y, Ovalle C, Valderrama L, Muvdi S, Rodríguez I, Gomez MA, Saravia NG. Miltefosine and Antimonial Drug Susceptibility of Leishmania Viannia Species and Populations in Regions of High Transmission in Colombia. PLOS Neglected Tropical Diseases 2014, 8: e2871. PMID: 24853871, PMCID: PMC4031164, DOI: 10.1371/journal.pntd.0002871.Peer-Reviewed Original ResearchConceptsV. panamensisLine treatmentClinical strainsDrug susceptibilitySecond-line treatmentFirst-line treatmentEmergence of resistancePopulations of LeishmaniaViannia speciesResistant clinical strainsAntimony susceptibilityClinical evidenceMeglumine antimoniatePentavalent antimonialsDermal leishmaniasisEpidemiologic differencesLeishmania VianniaProxy markerIntracellular amastigotesMunicipality of TumacoResistant strainsMiltefosineDisparate susceptibilityDrugsL. panamensis
2008
Antimony Resistance and Trypanothione in Experimentally Selected and Clinical Strains of Leishmania panamensis
Goyeneche-Patino DA, Valderrama L, Walker J, Saravia NG. Antimony Resistance and Trypanothione in Experimentally Selected and Clinical Strains of Leishmania panamensis. Antimicrobial Agents And Chemotherapy 2008, 52: 4503-4506. PMID: 18824610, PMCID: PMC2592887, DOI: 10.1128/aac.01075-08.Peer-Reviewed Original Research
2007
Pharmacokinetics of Antimony in Children Treated for Leishmaniasis with Meglumine Antimoniate
Cruz A, Rainey PM, Herwaldt BL, Stagni G, Palacios R, Trujillo R, Saravia NG. Pharmacokinetics of Antimony in Children Treated for Leishmaniasis with Meglumine Antimoniate. The Journal Of Infectious Diseases 2007, 195: 602-608. PMID: 17230422, DOI: 10.1086/510860.Peer-Reviewed Original ResearchConceptsPharmacokinetics of antimonyMeglumine antimoniateDrug exposureIntramuscular meglumine antimoniateWeight-adjusted clearancePeak concentrationPotential clinical relevanceTime-concentration curveLower peak concentrationsAntimonial therapyPharmacokinetic differencesCutaneous leishmaniasisClinical relevanceChildren 3Day 20Clearance rateAntimoniateLeishmaniasisAdultsChildrenSecond groupFirst groupPharmacokineticsDaysExposure
2006
Resistance to Antimony and Treatment Failure in Human Leishmania (Viannia) Infection
Rojas R, Valderrama L, Valderrama M, Varona MX, Ouellette M, Saravia NG. Resistance to Antimony and Treatment Failure in Human Leishmania (Viannia) Infection. The Journal Of Infectious Diseases 2006, 193: 1375-1383. PMID: 16619185, DOI: 10.1086/503371.Peer-Reviewed Original ResearchConceptsTreatment failureMeglumine antimoniatePrimary resistanceAntimonial drugsSecondary resistanceDrug resistanceHuman Leishmania infectionsEffective immune responseAnthroponotic visceral leishmaniasisAmerican cutaneous leishmaniasisAntimonial therapyStandard treatmentCutaneous diseaseLeishmania infectionTherapeutic responseImmune responseCutaneous leishmaniasisVisceral leishmaniasisAnthroponotic transmissionResistant organismsEffective doseIntracellular amastigotesSusceptible strainsAntimoniatePatients
2005
Role of the ABC Transporter MRPA (PGPA) in Antimony Resistance in Leishmania infantum Axenic and Intracellular Amastigotes
Fadili K, Messier N, Leprohon P, Roy G, Guimond C, Trudel N, Saravia NG, Papadopoulou B, Légaré D, Ouellette M. Role of the ABC Transporter MRPA (PGPA) in Antimony Resistance in Leishmania infantum Axenic and Intracellular Amastigotes. Antimicrobial Agents And Chemotherapy 2005, 49: 1988-1993. PMID: 15855523, PMCID: PMC1087671, DOI: 10.1128/aac.49.5.1988-1993.2005.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntimonyAntimony Sodium GluconateATP-Binding Cassette TransportersCell LineCysteineDNA, ProtozoanDrug ResistanceGlutathioneLeishmania infantumMembrane GlycoproteinsMicroscopy, ConfocalMonocytesOligonucleotide Array Sequence AnalysisProtozoan ProteinsRibonucleoproteinsSaccharomyces cerevisiae ProteinsSpermidineTransfectionConceptsABC transporter MRPAAntimony resistanceSodium stibogluconate (SSG) resistanceTreatment of infectionsMRPA geneSodium stibogluconateAntimonial compoundsMain drugsAmastigote parasitesPutative alterationsIntracellular amastigotesLevel of expressionProtozoan parasite LeishmaniaIntracellular parasitesAxenic amastigotesButhionine sulfoximineLevels of cysteineAmastigote stageDNA microarraysS-adenosylhomocysteine hydrolaseParasite LeishmaniaPotassium antimonyl tartrateAmastigotesLeishmaniaGenes
2004
Efficacy and toxicity of pentavalent antimonials (Glucantime and Pentostam) in an American cutaneous leishmaniasis animal model: luminometry application.
Henao HH, Osorio Y, Saravia NG, Gómez A, Travi B. Efficacy and toxicity of pentavalent antimonials (Glucantime and Pentostam) in an American cutaneous leishmaniasis animal model: luminometry application. Biomédica 2004, 24: 393-402. PMID: 15678803, DOI: 10.7705/biomedica.v24i4.1289.Peer-Reviewed Original ResearchConceptsAnti-Leishmania treatmentNormal serum levelsFirst-line drugsRight hind footSite of injectionParasitological efficacySerum levelsClinical efficacyLesion reductionCure rateLine drugsPentavalent antimonialsSimilar efficacyHepatic alterationsAlanine aminotransferaseLocal toxicityClinical observationsMicroscopic signsTreatment efficacyAnimal modelsHigh dosesLeishmania panamensisAspartate aminotransferaseParasite burdenGlucantime
2003
Antimony Uptake Systems in the Protozoan Parasite Leishmania and Accumulation Differences in Antimony-Resistant Parasites
Brochu C, Wang J, Roy G, Messier N, Wang XY, Saravia NG, Ouellette M. Antimony Uptake Systems in the Protozoan Parasite Leishmania and Accumulation Differences in Antimony-Resistant Parasites. Antimicrobial Agents And Chemotherapy 2003, 47: 3073-3079. PMID: 14506011, PMCID: PMC201146, DOI: 10.1128/aac.47.10.3073-3079.2003.Peer-Reviewed Original Research